Health Condition 1: G437- Chronic migraine without aura
Conditions
Interventions
Intervention1: Natrium muriaticum in centesimal potency: Medicine will be prescribed at baseline and followed up each month for next three months
Control Intervention1: Individualized Homoeopathic Med
Sponsors
Subhashree Modak
Eligibility
Inclusion criteria
Inclusion criteria: Adults aged between 18 and 60 years. A clinical diagnosis of chronic migraine, defined as headache occurring on 15 or more days per month for a duration of at least three consecutive months. On at least 8 days/month, the headache should fulfill criteria for migraine without aura (1.1), or respond to migraine-specific treatment (e.g., triptans, ergot derivatives)., in accordance with the International Classification of Headache Disorders, 3rd edition (ICHD-3). MIDAS score is greater than or equal to 6. Willingness to provide written informed consent and comply with study procedures. Not taking any other homeopathic treatment during the study period. Willing to report and refrain from starting new allopathic or alternative interventions for migraine during the study.
Exclusion criteria
Exclusion criteria: Presence of a secondary headache disorder (e.g., attributed to trauma, vascular disorders, intracranial neoplasms, infections, substance use/withdrawal, or psychiatric illness, as defined by ICHD-3 (e.g., code 6 12). Other Primary Headache Disorders: Diagnosed with cluster headache, chronic tension-type headache without migraine features, medication overuse headache, or hemiplegic/basilar migraine. Severe Uncontrolled Comorbidities: Uncontrolled hypertension, diabetes mellitus, renal, hepatic, or cardiac diseases that may interfere with study outcomes. Coexisting severe psychiatric conditions (such as History of major depression, bipolar disorder, or schizophrenia etc.) that may interfere with assessment. Pregnancy or lactation. Use of ongoing prophylactic headache medication that cannot be safely discontinued. Unwillingness to adhere to study protocol or provide written informed consent. Concurrent enrollment in another clinical trial within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Migraine Disability Assessment Scale (MIDAS) to assess impact on daily functioningTimepoint: At baseline and three months | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale (VAS) for headache intensity. Frequency of chronic headache attacks (monthly).Timepoint: At baseline and three months | — |
Countries
India
Contacts
Public ContactProf Dr Kaushik Deb Das
The Culcutta Homoeopathic Medical College and Hospital
Outcome results
None listed